Coronavirus disease 2019, superinfections, and antimicrobial development: What can we expect?

Clinical Infectious Diseases

Volumn 71, Issue 10, 2020, Pages 2736-2743

  Clancy, Cornelius J ^a   Hong Nguyen, M ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Antimicrobial development; Antimicrobial resistance; Coronavirus disease 2019; COVID 19; Superinfections

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL STEWARDSHIP; ANTIMICROBIAL THERAPY; CORONAVIRUS DISEASE 2019; DRUG USE; HUMAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; REIMBURSEMENT; REVIEW; SUPERINFECTION; SUSTAINABLE DEVELOPMENT;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; COVID-19; HUMANS; PROSPECTIVE STUDIES; SARS-COV-2; SUPERINFECTION;

EID: 85100038690     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciaa524     Document Type: Review

References (49)

1. Osterholm MT. Preparing for the next pandemic. N Engl J Med 2005; 352:1839–42.
2. Talbot GH, Jezek A, Murray BE, et al. The Infectious Diseases Society of America’s 10 x’20 initiative (10 new systemic antibacterial agents US Food and Drug Administration approved by 2020): is 20 x’20 a possibility? Clin Infect Dis 2019; 69:1–11.
3. Morens DM, Taubenberger JK, Fauci AS. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis 2008; 198:962–70.
4. van de Veerdonk FL, Gresnigt MS, Romani L, Netea MG, Latge JP. Aspergillus fumigatus morphology and dynamic host interactions. Nat Rev Microbiol 2017; 15:661–74.
5. Schauwvlieghe AFAD, Rijnders BJA, Philips N, et al; Dutch-Belgian Mycosis Study Group. Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: a retrospective cohort study. Lancet Respir Med 2018; 6:782–92.
6. Jernigan JA, Hatfield KM, Wolford H, et al. Multidrug-resistant bacterial infections in U.S. hospitalized patients, 2012–2017. N Engl J Med 2020; 382:1309–19.
7. Centers for Disease Control and Prevention. Antimicrobial resistance threats in the United States, 2019. Available at: https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf. Accessed 26 April 2020.
8. Review on Antimicrobial Resistance; O’Neill J, Chair. Tackling drug-resistant infections globally: final report and recommendations. 2016. Available at:https:// amr-review.org/sites/default/files/160518_Final%20paper_with%20cover.pdf. Accessed 2 May 2020.
9. Rex J. Tetraphase sold for $14m … and $600m goes up in smoke! Antimicrobial resistance solutions blog. 2020. Available at: https://amrsolutions/2020/03/23/ tetraphase-sold-for-14m-and-600m-goes-up-in-smoke/. Accessed 26 April 2020.
10. Clancy CJ, Potoski BA, Buehrle D, Nguyen MH. Estimating the treatment of carbapenem-resistant Enterobacteriaceae infections in the United States using antibiotic prescription data. Open Forum Infect Dis 2019; 6:ofz344.
11. Vickers RJ, Bassetti M, Clancy CJ, et al. Combating resistance while maintaining innovation: the future of antimicrobial stewardship. Future Microbiol 2019; 14:1331–41.
12. Boucher HW, File TM, Fowler VG, Jezek A, Rex JH, Outterson K. Antibiotic development incentives that reflect societal value of antibiotics [manuscript published online ahead of print 30 January 2020]. Clin Infect Dis 2020. doi:10.1093/ cid/ciaa092.
13. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395:497–506.
14. Chen T, Wu D, Chen H, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020; 368:m1091.
15. Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395:507–13.
16. Yang X, Yu Y, Xu J, et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study [manuscript published online ahead of print 24 February 2020]. Lancet Respir Med 2020. doi:10.1016/S2213-2600(20)30079-5.
17. Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med 2020; 382:1708–20.
18. Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 2020; 395:1054–62.
19. Wang Z, Yang B, Li Q, Wen L, Zhang R. Clinical features of 69 cases with coronavirus disease 2019 in Wuhan, China. Clin Infect Dis 2020; 71:769–77.
20. Dong X, Cao YY, Lu XX, et al. Eleven faces of coronavirus disease 2019 [manuscript published online ahead of print 20 March 2020]. Allergy 2020. doi:10.1111/ all.14289.
21. Cao J, Tu WJ, Cheng W, et al. Clinical features and short-term outcomes of 102 patients with coronavirus disease 2019 in Wuhan, China. Clin Infect Dis 2020; 71:748–55.
22. Lian J, Jin X, Hao S, et al. Analysis of epidemiological and clinical features in older patients with coronavirus disease 2019 (COVID-19) out of Wuhan. Clin Infect Dis 2020; 71:740–7.
23. Du Y, Tu L, Zhu P, et al. Clinical features of 85 fatal cases of COVID-19 from Wuhan: a retrospective observational study [manuscript published online ahead of print 3 April 2020]. Am J Respir Crit Care Med 2020. doi:10.1164/ rccm.202003-0543OC.
24. Chen X, Zhao B, Qu Y, et al. Detectable serum SARS-CoV-2 viral load (RNAaemia) is closely correlated with drastically elevated interleukin 6 (IL-6) level in critically ill COVID-19 patients. Clin Infect Dis 2020; 71:1937–42.
25. Goyal P, Choi JJ, Pinheiro LC, et al. Clinical characteristics of Covid-19 in New York City [manuscript published online ahead of print 17 April 2020]. N Engl J Med 2020. doi:10.1056/NEJMc2010419.
26. Lescure FX, Bouadma L, Nguyen D, et al. Clinical and virological data of the first cases of COVID-19 in Europe: a case series [manuscript published online ahead of print 27 March 2020]. Lancet Infect Dis 2020. doi:10.1016/ S1473-3099(20)30200-0.
27. Arentz M, Yim E, Klaff L, et al. Characteristics and outcomes of 21 critically Ill patients with COVID-19 in Washington State [manuscript published online ahead of print 19 March 2020]. JAMA 2020. doi:10.1001/jama.2020.4326.
28. Bhatraju PK, Ghassemieh BJ, Nichols M, et al. Covid-19 in critically Ill patients in the Seattle region—case series [manuscript published online ahead of print 30 March 2020]. N Engl J Med 2020. doi:10.1056/NEJMoa2004500.
29. Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China [manuscript published online ahead of print 7 March 2020]. JAMA 2020. doi:10.1001/ jama.2020.1585.
30. Grasselli G, Zangrillo A, Zanella A, et al. Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy [manuscript published online ahead of print 6 April 2020]. JAMA 2020. doi:10.1001/jama.2020.5394.
31. Centers for Disease Control and Prevention. Coronavirus disease 2019: infection control guidance. Atlanta, GA: CDC, 2020.
32. Chen G, Wu D, Guo W, et al. Clinical and immunologic features in severe and moderate coronavirus disease 2019. J Clin Invest 2020; 130:2620–9.
33. Pedersen SF, Ho YC. SARS-CoV-2: a storm is raging. J Clin Invest 2020; 130:2202–5.
34. Barker K. Lawmakers, experts warn of U.S. reliance on foreign-made drugs, medical products. Joplin Globe 2020. Available at: https://www.joplinglobe.com/news/local_news/lawmakers-experts-warn-of-u-s-reliance-on-foreign-made/article_cc1332e0-e7e7-5cba-9089-f9ec5bf8a3f6.html. Accessed 2 May 2020.
35. Hsu LY, Apisarnthanarak A, Khan E, Suwantarat N, Ghafur A, Tambyah PA. Carbapenem-resistant Acinetobacter baumannii and Enterobacteriaceae in South and Southeast Asia. Clin Microbiol Rev 2017; 30:1–22.
36. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1–12.
37. Spellberg B, Powers JH, Brass EP, Miller LG, Edwards JE Jr. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis 2004; 38:1279–86.
38. US Food and Drug Administration. Novel drug approvals. Silver Spring, MD: FDA, 2020.
39. Carr A. Antibiotic and antifungal update September 2019. New York, NY: Needham & Company, 2019.
40. World Health Organization. Antibacterial agents in clinical development: an analysis of the antibacterial clinical development pipeline. Geneva, Switzerland: WHO, 2019.
41. Theuretzbacher U, Bush K, Harbarth S, et al. Critical analysis of antibacterial agents in clinical development. Nat Rev Microbiol 2020; 18:286–98.
42. Rex J. Novel biology, novel utility, and the illusion of skill: What to develop? What to reward? Antimicrobial resistance solutions blog. 2020. Available at: https:// amrsolutions/2020/02/09/novel-biology-novel-utility-the-illusion-of-skill-what-to-develop-what-to-reward/.
43. Årdal C, Røttingen JA, Opalska A, Van Hengel AJ, Larsen J. Pull incentives for antibacterial drug development: an analysis by the Transatlantic Task Force on Antimicrobial Resistance. Clin Infect Dis 2017; 65:1378–82.
44. Rome BN, Kesselheim AS. Transferrable market exclusivity extensions to promote antibiotic development: an economic analysis. Clin Infect Dis 2020; 71:1671–5.
45. Clancy CJ, Nguyen MH. Estimating the size of the United States market for new antibiotics with activity against carbapenem-resistant Enterobacteriaceae [manuscript published online ahead of print 7 October 2019]. Antimicrob Agents Chemother 2019. doi:10.1128/AAC.01733-19.
46. Rex J. New mechanisms for antibiotic reimbursement in the United States: CMS’s IPPS FY2020 final rule. Antimicrobial resistance solutions blog. 2019. Available at: http://amrsolutions/blog/new-mechanisms-for-antibiotic-reimbursement-in-the-united-states-cmss-ipps-fy2020-final-rule/.
47. Healio Infectious Diseases News. BARDA awards Paratek up to $285 million to develop anthrax treatment. 2019. Available at: https://www.healio.com/ infectious-disease/respiratory-infections/news/online/%7B7a3f4709-8507-448fb6cc-a8ce4e0b1215%7D/barda-awards-paratek-up-to-285-million-to-developanthrax-treatment. Accessed 2 May 2020.
48. Nielsen TB, Brass EP, Gilbert DN, Bartlett JG, Spellberg B. Sustainable discovery and development of antibiotics—is a nonprofit approach the future? N Engl J Med 2019; 381:503–5.
49. Rex J. Melinta, part 2 / bankruptcy is not the end/post-approval costs for an antibiotic. Antimicrobial resistance solutions blog. 2020. Available at: https:// amrsolutions/2020/01/07/melinta-part-2-bankruptcy-is-not-the-end-postapproval-costs-for-an-antibiotic/. Accessed 2 May 2020.